이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
Shandong Weigao Group Medical Polymer 관리
관리 기준 확인 3/4
현재 CEO에 대한 정보가 충분하지 않습니다.
주요 정보
Rinan Cong
최고 경영자
CN¥4.0m
총 보상
| CEO 급여 비율 | 42.1% |
| CEO 임기 | no data |
| CEO 소유권 | 0.05% |
| 경영진 평균 재임 기간 | 2.1yrs |
| 이사회 평균 재임 기간 | 2.1yrs |
최근 관리 업데이트
Recent updates
Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) 27% Share Price Plunge Could Signal Some Risk
Jun 25
Here's What To Make Of Shandong Weigao Group Medical Polymer's (HKG:1066) Decelerating Rates Of Return
Jun 23Shandong Weigao Group Medical Polymer's (HKG:1066) Shareholders Will Receive A Bigger Dividend Than Last Year
May 31We Think Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) CEO Compensation Package Needs To Be Put Under A Microscope
May 22Earnings Not Telling The Story For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066)
Apr 23Analysts Have Lowered Expectations For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) After Its Latest Results
Mar 28Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) Shares May Have Run Too Fast Too Soon
Jan 09Returns On Capital Are Showing Encouraging Signs At Shandong Weigao Group Medical Polymer (HKG:1066)
Dec 22Are Investors Undervaluing Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) By 44%?
Nov 10Does Shandong Weigao Group Medical Polymer (HKG:1066) Have A Healthy Balance Sheet?
Oct 05Return Trends At Shandong Weigao Group Medical Polymer (HKG:1066) Aren't Appealing
Aug 01Is Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Trading At A 28% Discount?
Jul 19Shandong Weigao Group Medical Polymer (HKG:1066) Ticks All The Boxes When It Comes To Earnings Growth
Jun 22Is Shandong Weigao Group Medical Polymer (HKG:1066) Using Too Much Debt?
Jun 09The Returns At Shandong Weigao Group Medical Polymer (HKG:1066) Aren't Growing
Apr 27Shandong Weigao Group Medical Polymer (HKG:1066) Ticks All The Boxes When It Comes To Earnings Growth
Mar 17A Look At The Intrinsic Value Of Shandong Weigao Group Medical Polymer Company Limited (HKG:1066)
Feb 27Returns On Capital At Shandong Weigao Group Medical Polymer (HKG:1066) Have Hit The Brakes
Jan 18Does Shandong Weigao Group Medical Polymer (HKG:1066) Have A Healthy Balance Sheet?
Dec 12Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Shares Could Be 21% Below Their Intrinsic Value Estimate
Nov 29Here's Why We Think Shandong Weigao Group Medical Polymer (HKG:1066) Might Deserve Your Attention Today
Nov 14Shandong Weigao Group Medical Polymer (HKG:1066) Is Paying Out A Larger Dividend Than Last Year
Oct 03The Returns At Shandong Weigao Group Medical Polymer (HKG:1066) Aren't Growing
Sep 21Shandong Weigao Group Medical Polymer (HKG:1066) Could Easily Take On More Debt
Sep 05Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) Intrinsic Value Is Potentially 27% Above Its Share Price
Aug 23Here's Why Shandong Weigao Group Medical Polymer (HKG:1066) Has Caught The Eye Of Investors
Aug 08There's Been No Shortage Of Growth Recently For Shandong Weigao Group Medical Polymer's (HKG:1066) Returns On Capital
Jun 22Shandong Weigao Group Medical Polymer (HKG:1066) Will Pay A Smaller Dividend Than Last Year
Jun 08An Intrinsic Calculation For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Suggests It's 27% Undervalued
May 16Is Shandong Weigao Group Medical Polymer (HKG:1066) A Risky Investment?
May 03Shandong Weigao Group Medical Polymer's (HKG:1066) Returns On Capital Are Heading Higher
Mar 17Is There An Opportunity With Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) 42% Undervaluation?
Jan 28Does Shandong Weigao Group Medical Polymer (HKG:1066) Deserve A Spot On Your Watchlist?
Jan 13Returns Are Gaining Momentum At Shandong Weigao Group Medical Polymer (HKG:1066)
Dec 17Shandong Weigao Group Medical Polymer (HKG:1066) Seems To Use Debt Rather Sparingly
Dec 05An Intrinsic Calculation For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Suggests It's 32% Undervalued
Oct 18Do Shandong Weigao Group Medical Polymer's (HKG:1066) Earnings Warrant Your Attention?
Oct 06Shandong Weigao Group Medical Polymer (HKG:1066) Shareholders Will Want The ROCE Trajectory To Continue
Sep 10Shandong Weigao Group Medical Polymer (HKG:1066) Has A Rock Solid Balance Sheet
Aug 29Calculating The Fair Value Of Shandong Weigao Group Medical Polymer Company Limited (HKG:1066)
Jul 09Here's Why I Think Shandong Weigao Group Medical Polymer (HKG:1066) Might Deserve Your Attention Today
Jun 26Investors Met With Slowing Returns on Capital At Shandong Weigao Group Medical Polymer (HKG:1066)
Jun 02These 4 Measures Indicate That Shandong Weigao Group Medical Polymer (HKG:1066) Is Using Debt Reasonably Well
Apr 24CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Dec 31 2023 | CN¥4m | CN¥2m | CN¥2b |
| Sep 30 2023 | n/a | n/a | CN¥2b |
| Jun 30 2023 | n/a | n/a | CN¥2b |
| Mar 31 2023 | n/a | n/a | CN¥3b |
| Dec 31 2022 | CN¥5m | CN¥950k | CN¥3b |
| Sep 30 2022 | n/a | n/a | CN¥3b |
| Jun 30 2022 | n/a | n/a | CN¥3b |
| Mar 31 2022 | n/a | n/a | CN¥2b |
| Dec 31 2021 | CN¥3m | CN¥903k | CN¥2b |
보상 대 시장: Rinan 의 총 보상 ($USD 549.82K )은 Hong Kong 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 452.40K ).
보상과 수익: Rinan 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.
CEO
Rinan Cong (43 yo)
no data
테뉴어
CN¥3,990,000
보상
Mr. Rinan Cong served as Chief Executive Officer at Shandong Weigao Group Medical Polymer Company Limited since March 30, 2021 until 2024 and served as Executive Director since May 24, 2021 until 2024 and...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Executive Chairman of the Board & Compliance Officer | 5.6yrs | CN¥8.27m | 0.14% CN¥ 24.1m | |
| Chief Executive Officer | no data | CN¥3.99m | 0.048% CN¥ 8.2m | |
| Executive Director | 2.1yrs | CN¥1.32m | 데이터 없음 | |
| Chief Financial Officer | 7.4yrs | 데이터 없음 | 데이터 없음 | |
| Non-Executive Director | less than a year | 데이터 없음 | 데이터 없음 | |
| Executive Director | less than a year | 데이터 없음 | 0.011% CN¥ 1.9m | |
| Company Secretary | 18.2yrs | 데이터 없음 | 데이터 없음 |
2.1yrs
평균 재임 기간
49yo
평균 연령
경험이 풍부한 관리: 1066 의 관리팀은 경험 ( 2 년 평균 재직 기간)으로 간주됩니다.
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Executive Chairman of the Board & Compliance Officer | 5.6yrs | CN¥8.27m | 0.14% CN¥ 24.1m | |
| Executive Director | 2.1yrs | CN¥1.32m | 데이터 없음 | |
| Non-Executive Director | less than a year | 데이터 없음 | 데이터 없음 | |
| Executive Director | less than a year | 데이터 없음 | 0.011% CN¥ 1.9m | |
| Non-Executive Director | 3.3yrs | 데이터 없음 | 데이터 없음 | |
| Independent Non-Executive Director | 1.8yrs | CN¥150.00k | 데이터 없음 | |
| Independent Non-Executive Director | 2.1yrs | CN¥207.00k | 데이터 없음 | |
| Vice Chairman | 3.3yrs | 데이터 없음 | 데이터 없음 | |
| Chairman of the Supervisors | 4yrs | 데이터 없음 | 데이터 없음 | |
| Employee Representative Supervisor | 2.3yrs | 데이터 없음 | 데이터 없음 | |
| Independent Non-Executive Director | 1.6yrs | CN¥150.00k | 데이터 없음 | |
| Independent Non-Executive Director | less than a year | 데이터 없음 | 데이터 없음 |
2.1yrs
평균 재임 기간
49yo
평균 연령
경험이 풍부한 이사회: 1066 의 이사회는 경험(평균 재직 기간 2 년)으로 간주되지 않으므로 새 이사회가 필요합니다.